Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma By Ogkologos - December 10, 2025 363 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II cohort of the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) New ESMO President 2029-2030 Elected MOST POPULAR A call to action: how our Campaigns Ambassadors are shaping the... May 6, 2022 Nivolumab Plus AVD Prolongs PFS in Adolescents and Adults with Advanced-Stage... October 30, 2024 Adjuvant Pembrolizumab Continues to Demonstrate a Clinically Meaningful DMFS Benefit in... March 14, 2024 Fisioterapeutas en oncología October 12, 2021 Load more HOT NEWS Mohs Surgery for Skin Cancer: What to Know and What to... Motixafortide May Improve Stem Cell Transplants for People with Multiple Myeloma FDA Approves Liquid Biopsy NGS Companion Diagnostic Test for Multiple Cancers... Some Children with Liver Cancer May Need Less Chemotherapy, Study Suggests
